- Trials with a EudraCT protocol (41)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
41 result(s) found for: Holter monitor.
Displaying page 1 of 3.
EudraCT Number: 2018-001518-13 | Sponsor Protocol Number: 10407 | Start Date*: 2018-11-12 |
Sponsor Name:Maatschap Cardiologie Zwolle | ||
Full Title: Comparison between treatment with catheter ablation or anti-arrhythmic drugs (sotalol or combination of verapamil and flecainide) of patients with benign ventricular premature beats and ventricular... | ||
Medical condition: Premature ventricular beats, ventricular ectopy, ventricle tachycardia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000042-30 | Sponsor Protocol Number: GS-US-372-1234 | Start Date*: 2015-05-18 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects with Long QT-3 Syndrome | |||||||||||||
Medical condition: Subjects with an established diagnosis of LQT3. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013293-41 | Sponsor Protocol Number: 08/0182 | Start Date*: 2011-03-21 |
Sponsor Name:Joint UCLH/UCH Biomedical Research Unit | ||
Full Title: Randomised, double blind, phase IV study to compare the incidence of ECG changes during elective caesarean section under spinal anaesthesia when using phenylephrine or ephedrine infusion to maintai... | ||
Medical condition: uncomplicated term pregnancy. Patient undergoing elective cesarean delivery. Ephedrine and phenylephrine are vasopressors used to maintain maternal blood pressure close to normal values during spin... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-000671-17 | Sponsor Protocol Number: 3163 K1-200-WW | Start Date*: 2005-10-05 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development | ||
Full Title: A Safety and Efficacy Dose-Ranging Study of GAP-486 in Subjects With Nonsustained Ventricular Tachycardia and Acute Ischemia | ||
Medical condition: Subjects with coronary artery disease or left ventricular dysfunction experiencing an acute coronary syndrome with non-life-threatening ventricular arrhythmias. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) GB (Prematurely Ended) SE (Prematurely Ended) DK (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001483-21 | Sponsor Protocol Number: KBT009 | Start Date*: 2011-06-15 | |||||||||||
Sponsor Name:Karo Bio AB | |||||||||||||
Full Title: A Placebo-controlled, Double-blind, Randomised, Parallel-group, Long-term Phase III Trial Assessing the Safety and Efficacy of 50 µg and 100 µg/day of eprotirome in Patients with Heterozygous Famil... | |||||||||||||
Medical condition: Heterozygous Familial Hypercholesterolaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) DK (Completed) CZ (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004761-34 | Sponsor Protocol Number: 150-CL-012 | Start Date*: 2007-04-19 | |||||||||||
Sponsor Name:Astellas US Pharma US Inc.(APUS) | |||||||||||||
Full Title: A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability and Pharmacodynamics of YM150 in Subjects with Non-Valvular Atrial Fibrillation. | |||||||||||||
Medical condition: Prevention of stroke on patients with Non-Valvular Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006614-37 | Sponsor Protocol Number: CryoStopPersAF | Start Date*: 2022-05-11 | |||||||||||
Sponsor Name:Region Örebro | |||||||||||||
Full Title: First-line cryoablation for early treatment of Persistent Atrial Fibrillation – a randomized study comparing early trigger isolation using the Cryoballoon versus antiarrhythmic medication. | |||||||||||||
Medical condition: Persistent symptomatic atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001382-15 | Sponsor Protocol Number: ATI-2042-CLN-205 | Start Date*: 2007-09-20 | |||||||||||
Sponsor Name:ARYx Therapeutics | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of ATI-2042 in Patients with Paroxysmal Atrial Fibrillation and Pacemakers with Atrial Fibrillation Data Logging Capabilities | |||||||||||||
Medical condition: The trial is to investigate the efficacy of the new drug ATI-2042 to reduce the atrial tachyarrhythmia burden in patients with paroxysmal atrial fabrilation. ATI-2042 is designed to act like Amioda... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005688-36 | Sponsor Protocol Number: SCIVF2021 | Start Date*: 2022-09-19 |
Sponsor Name:Amsterdam UMC | ||
Full Title: Quinidine versus verapamil in short-coupled idiopathic ventricular fibrillation: An open label, randomized crossover pilot trial | ||
Medical condition: Short-coupled idiopathic ventricular fibrillation is a rare syndrome and subtype of idiopathic ventricular fibrillation that is characterized by ventricular fibrillation or polymorphic ventricular ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001683-37 | Sponsor Protocol Number: 2018012805 | Start Date*: 2018-07-03 |
Sponsor Name:Rigshospitalet | ||
Full Title: The RIME-IVF study Investigation of RIsk factors in out-of-hospital-cardiac-arrest patients, and MEdical treatment in Idiopathic Ventricular Fibrillation patients | ||
Medical condition: Unexplained cardiac arrest patients after thorough investigations (Idiopathic ventricular fibrillation, IVF) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001282-34 | Sponsor Protocol Number: ITOFD04-01 | Start Date*: 2005-07-30 |
Sponsor Name:AXCAN PHARMA Inc. | ||
Full Title: A multicentre, randomized, double-blind, placebo-controlled study of the efficacy and safety of itopride HCl in patients suffering from functional dyspepsia | ||
Medical condition: Treatment of abdominal symptoms in patients with functional dyspepsia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-004522-16 | Sponsor Protocol Number: DU176b-C-U301 | Start Date*: 2009-05-20 | |||||||||||
Sponsor Name:Daiichi Sankyo Pharma Development | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MULTI-CENTER, MULTI-NATIONAL STUDY FOR EVALUATION OF EFFICACY AND SAFETY OF DU-176B VERSUS WARFARIN IN SUBJECTS WITH ATRIAL FIBRIL... | |||||||||||||
Medical condition: Reduction of Stroke and/or systemic embolic event (SEE) in subjects with atrial fibrillation (AF). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (Completed) SE (Completed) EE (Completed) FI (Completed) NL (Completed) PT (Completed) DK (Completed) ES (Completed) CZ (Completed) IT (Completed) BG (Completed) HU (Completed) SK (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001529-18 | Sponsor Protocol Number: LGN-VN-003 | Start Date*: 2015-08-18 |
Sponsor Name:Laguna Pharmaceuticals, Inc. | ||
Full Title: RESTORE SR: A multi-center, Randomized, double-blind, placebo-controlled study to Evaluate the Safety and efficacy of a single oral dose of vanoxerine for The conversion Of subjects with REcent ons... | ||
Medical condition: Recent atrial fibrillation (AF) or atrial flutter (AFL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) NL (Ongoing) PL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004826-32 | Sponsor Protocol Number: 3121001 | Start Date*: 2016-10-24 | |||||||||||
Sponsor Name:Orion Corporation Orion Pharma | |||||||||||||
Full Title: Safety and pharmacokinetics of ODM-207 in patients with selected advanced solid tumours: an open-label, non-randomised, uncontrolled, multicentre, first-in-human study with cohort expansion | |||||||||||||
Medical condition: Advanced Solid Tumours | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FI (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003148-21 | Sponsor Protocol Number: DU176b-F-E308 | Start Date*: 2014-06-17 | |||||||||||
Sponsor Name:Daiichi Sankyo Development Ltd | |||||||||||||
Full Title: A prospective, randomised, open-label, blinded endpoint evaluation (PROBE) parallel group study comparing edoxaban (DU-176b) with enoxaparin/warfarin followed by warfarin alone in subjects undergoi... | |||||||||||||
Medical condition: Stroke and thromboembolism prevention in patients with non-valvular atrial fibrillation (NVAF) undergoing planned electrical cardioversion. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) DE (Completed) GB (Completed) HU (Completed) IT (Completed) DK (Completed) ES (Completed) AT (Completed) CZ (Completed) NL (Completed) RO (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001520-34 | Sponsor Protocol Number: D5982C00007 | Start Date*: 2021-01-12 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Me... | |||||||||||||
Medical condition: Severe and inadequately controlled asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) NL (Completed) BG (Trial now transitioned) BE (Completed) PL (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002547-25 | Sponsor Protocol Number: ARC1779-003 | Start Date*: 2007-12-19 | ||||||||||||||||
Sponsor Name:Archemix Corp. | ||||||||||||||||||
Full Title: A Phase 2 Study of an Aptameric von Willebrand Factor Antagonist, ARC1779, in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention | ||||||||||||||||||
Medical condition: ACS Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention (ST segemnt elevation MI and Non ST segemtn elevation MI) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001818-42 | Sponsor Protocol Number: C41750/3100 | Start Date*: 2016-04-14 | |||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
Full Title: A Double-blind, Randomized, Sham–procedure–controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) in Patients with Chronic Heart Failure D... | |||||||||||||
Medical condition: Chronic Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Prematurely Ended) GB (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001795-30 | Sponsor Protocol Number: DU176b-C-E314 | Start Date*: 2016-11-11 | |||||||||||
Sponsor Name:Daiichi Sankyo, Inc. | |||||||||||||
Full Title: Evaluation of Edoxaban in Anticoagulant Naïve Patients with Non-Valvular Atrial Fibrillation (NVAF) and high Creatinine Clearance | |||||||||||||
Medical condition: Non-Valvular Atrial Fibrillation (NVAF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) CZ (Completed) EE (Completed) LT (Completed) SK (Completed) DK (Completed) HU (Completed) ES (Completed) BE (Completed) PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001150-87 | Sponsor Protocol Number: 150-CL-021 | Start Date*: 2009-05-28 | |||||||||||
Sponsor Name:Astellas Pharma Europe B.V. | |||||||||||||
Full Title: A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study to Investigate the Safety and Tolerability of YM150 in Subjects with Non-Valvular Atrial Fibrillation and to Com... | |||||||||||||
Medical condition: the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) LV (Prematurely Ended) SK (Completed) DE (Completed) HU (Completed) FR (Completed) EE (Completed) ES (Completed) GB (Completed) CZ (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
